User profiles for M. K. Sutherland
Megan K SutherlandCenter for Technology in Government, University at Albany Verified email at ctg.albany.edu Cited by 135 |
[HTML][HTML] Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler, MK Sutherland, JC Geoghegan… - The EMBO …, 2003 - embopress.org
There is an unmet medical need for anabolic treatments to restore lost bone. Human genetic
bone disorders provide insight into bone regulatory processes. Sclerosteosis is a disease …
bone disorders provide insight into bone regulatory processes. Sclerosteosis is a disease …
[HTML][HTML] CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
…, M Anderson, RF Zabinski, MK Sutherland… - British journal of …, 2008 - nature.com
CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various
solid tumours including colorectal and glioblastomas. CD133 was found here to be highly …
solid tumours including colorectal and glioblastomas. CD133 was found here to be highly …
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
MK Sutherland, JC Geoghegan, C Yu, E Turcott… - Bone, 2004 - Elsevier
A null mutation in the SOST gene is associated with sclerosteosis, an inherited disorder
characterized by a high bone mass phenotype. The protein product of the SOST gene, sclerostin…
characterized by a high bone mass phenotype. The protein product of the SOST gene, sclerostin…
Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels
MK Sutherland, MJ Somerville, LKK Yoong… - Molecular Brain …, 1992 - Elsevier
Receptors for vitamin D hormone (VDR) and the calcium binding protein, calbindin-28k,
have been localized in many tissues, including brain. In brain, VDR and calbindin-28k were …
have been localized in many tissues, including brain. In brain, VDR and calbindin-28k were …
[HTML][HTML] Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex
…, JE Skonier, D Shpektor, MK Sutherland… - Journal of Biological …, 2004 - ASBMB
Noggin and sclerostin are bone morphogenetic protein (BMP) antagonists that modulate
mitogenic activity through sequestering BMPs. Little is known of the interactions among this …
mitogenic activity through sequestering BMPs. Little is known of the interactions among this …
Characterization of SGN-CD123A, a potent CD123-directed antibody–drug conjugate for acute myeloid leukemia
Abstract Treatment choices for acute myelogenous leukemia (AML) patients resistant to
conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor …
conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor …
[HTML][HTML] Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
…, KA Gordon, S Duniho, MK Sutherland… - British journal of …, 2010 - nature.com
Background: CD70 is an ideal target for antibody-based therapies because of its aberrant
high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted …
high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted …
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts
MK Sutherland, JC Geoghegan, C Yu, DG Winkler… - Bone, 2004 - Elsevier
SOST, a novel bone morphogenetic protein (BMP) antagonist and negative regulator of
bone formation, is expressed in osteogenic cells. Null mutations in the SOST gene are …
bone formation, is expressed in osteogenic cells. Null mutations in the SOST gene are …
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
MK Sutherland, C Yu, TS Lewis, JB Miyamoto… - MAbs, 2009 - Taylor & Francis
Despite therapeutic advances, the long-term survival rates for acute myeloid leukemia (AML)
are estimated to be 10% or less, pointing to the need for better treatment options. AML cells …
are estimated to be 10% or less, pointing to the need for better treatment options. AML cells …
Data-Driven Smart cities: A closer look at organizational, technical and data complexities
MK Sutherland, ME Cook - Proceedings of the 18th annual international …, 2017 - dl.acm.org
This management paper looks at the challenges faced by city governments as they build
their capability to leverage data to achieve the promise of a smarter city. While producing …
their capability to leverage data to achieve the promise of a smarter city. While producing …